^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Squamous Cell Carcinoma

    Related cancers:
    1d
    EC-CRT-008: Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC (clinicaltrials.gov)
    P3, N=242, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    Loqtorzi (toripalimab-tpzi) • capecitabine
    1d
    Gut microbiota diversity in patients with ESCC: associations with esophagectomy, the tumor immune microenvironment, and nivolumab response. (PubMed, Esophagus)
    Gut microbiota diversity was associated with the tumor immune microenvironment and nivolumab response in patients with esophageal cancer. Esophagectomy was also associated with alterations in gut microbial composition.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab)
    1d
    Heterogeneous nuclear ribonucleoprotein C deficiency compromises extracellular matrix-receptor interaction and induces apoptosis in esophageal cancer by targeting transcripts with complex structures. (PubMed, Biochim Biophys Acta Mol Basis Dis)
    Interestingly, mechanistic studies revealed that HNRNPC depletion promoted cell apoptosis without affecting proliferation, thereby inhibiting tumor growth. At the molecular level, HNRNPC deficiency selectively influenced transcripts with complex structures, such as CD44, OLFML2A, and PCSK6, and subsequently disrupted extracellular matrix-receptor interactions, leading to impeded tumor progression.
    Journal
    |
    HNRNPC (Heterogeneous Nuclear Ribonucleoprotein C)
    5d
    Targeting the ROS-JNK/p38 Axis: Schisandrin A as a Novel Therapeutic Candidate for Esophageal Squamous Cell Carcinoma. (PubMed, J Microbiol Biotechnol)
    Specific inhibitors (SP600125, SB203580, NAC, Z-vad-fmk) were employed to validate the underlying mechanisms...Sch A selectively induces apoptosis in ESCC cells through ROS-JNK/p38-mediated pathways, mitochondrial dysfunction, and cell cycle arrest. These findings indicate that Sch A is a promising therapeutic candidate for treating ESCC.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4)
    |
    SP600125
    6d
    A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Tookad (padeliporfin)
    6d
    A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer (clinicaltrials.gov)
    P1, N=60, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1 trial • Pan tumor
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MTAP (Methylthioadenosine Phosphorylase)
    |
    HER-2 overexpression • MTAP deletion
    |
    MSK-IMPACT • PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody • PD-L1 IHC 73-10 pharmDx
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • navlimetostat (BMS-986504)
    6d
    Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, The First Affiliated Hospital of Henan University of Science and Technology
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    6d
    Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=158, Not yet recruiting, Fudan University
    New trial
    6d
    PBK-Loaded secretory autophagosomes drive radiotherapy-induced systemic adipose depletion via MAPK/ERK-PRKA/PKA-LIPE/HSL signaling: a therapeutic target for esophageal cancer cachexia. (PubMed, Autophagy)
    Critically, pharmacological inhibition of PBK with OTS-514 rescued adipose mass in preclinical models while enhancing tumor radiosensitivity. Our work redefines radiotherapy-induced cachexia as an adipose-centric process orchestrated by SAPs, unveils PBK as a therapeutic target, and provides actionable biomarkers for early intervention. These findings bridge the gap between localized radiotherapy and systemic metabolic sequelae, offering a dual-strategy approach to improve both survival and quality of life in ESCC patients.
    Journal
    |
    MAPK1 (Mitogen-activated protein kinase 1) • PBK (PDZ Binding Kinase)
    |
    OTS514
    6d
    Molecular characteristics of proximal and distal esophagogastric junction adenocarcinoma. (PubMed, J Thorac Dis)
    Our NGS-based analysis revealed 10 high-frequency mutant genes in EGJA and demonstrated significant molecular differences among EGJA, GCA, and ESCC. These findings support the molecular basis for a distinct TNM staging system for EGJA.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ARID1A (AT-rich interaction domain 1A) • CCNE1 (Cyclin E1) • LRP1B (LDL Receptor Related Protein 1B) • FGF3 (Fibroblast growth factor 3) • CDK6 (Cyclin-dependent kinase 6) • FAT3 (FAT Atypical Cadherin 3) • SPTA1 (Spectrin Alpha) • SFTPA1 (Surfactant Protein A1)
    |
    TP53 mutation
    6d
    Cytotoxicity and potential cell death mechanisms of three new benzamidine derivatives in esophageal squamous cell carcinoma cells using in vitro and in silico approaches. (PubMed, Cytotechnology)
    The results showed that the cytotoxic effect of all three NBDs on KYSE-150 outperformed 5-fluorouracil (5-FU), with NBD 3 producing the highest cytotoxicity (IC50: 21.57 µM), followed by NBD 2 (IC50: 34.17 µM) and NBD 1 (IC50: 37.75 µM)...This study provides insights into the potential anticancer activities and the mechanistic pathway of NBDs in ESCC. The online version contains supplementary material available at 10.1007/s10616-026-00934-8.
    Preclinical • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • TNFA (Tumor Necrosis Factor-Alpha) • BCL2L2 (BCL2 Like 2) • AIM2 (Absent In Melanoma 2) • CASP9 (Caspase 9) • CDK7 (Cyclin Dependent Kinase 7) • FAS (Fas cell surface death receptor) • BCL2L10 (BCL2 like 10) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1) • AIFM2 (Apoptosis Inducing Factor Mitochondria Associated 2) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    |
    5-fluorouracil
    7d
    Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 (clinicaltrials.gov)
    P2, N=93, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • Meiyouheng (becotatug vedotin)